Developer docs
API playgroundTry for free, no card

Search company profiles

Theragenic

Full company profile

uuid002oonu

Namestring
Theragenic
Legal namestring
Theragenics Corporation
Websiteurl
theragenics.com
Company typeenum
Private
Founded yearint
1981
Descriptiontext

Theragenics Corporation is a private specialty medical device and radioisotope manufacturing company headquartered in Buford, Georgia, founded in 1981 as Nuclear Medicine, Inc. by Georgia Institute of Technology physicists. The company operates two principal business segments: (1) a brachytherapy franchise built around proprietary LDR brachytherapy seeds — TheraSeed® Palladium-103, AgX100® Iodine-125, and (since 2025) Cesium-131 distributed under license from GT Medical Technologies — together with a full ecosystem of delivery systems (TheraStrand®, TheraSleeve®, TheraLoad®, AnchorLoad®, C20™ cartridges, preloaded needle trays, intra-ocular carriers) and fiducial markers; and (2) a radioisotope contract manufacturing organization (CMO) business leveraging 14 cyclotrons at a 134,000 sq ft facility to produce Copper-64, Pd-103, I-125, Indium-111, Gallium-67, and Yttrium-90 for radiopharmaceutical partners, including a March 2026 large-scale Copper-64 supply agreement with Clarity Pharmaceuticals.

The company's business model combines direct sales of brachytherapy seeds and accessories to hospitals, cancer centers, and urology/radiation oncology practices across more than 40 countries, with multi-year B2B contract manufacturing agreements with pharmaceutical partners developing radiopharmaceuticals. GTM is sales-led for the medical device side, supported by industry conference participation (ABS, ASTRO, EANM, LUGPA) and a physician finder tool, while the CMO side is a dedicated B2B channel with named account management. Theragenics operates through wholly-owned subsidiaries Galt Medical (vascular/interventional devices, Garland TX), CP Medical (wound closure and specialty sutures, Norcross GA), and Arrotek Medical (medical device design consultancy with facilities in Sligo, Ireland and North Attleboro, MA). The company is owned by Juniper Investment Company following a mid-2010s take-private transaction.

Short descriptiontext

Theragenics is a private specialty medical device and radioisotope manufacturer operating 14 cyclotrons at a 134,000 sq ft facility in Buford, GA, producing LDR brachytherapy seeds (Pd-103, I-125, Cs-131), radioisotope CMO services for radiopharmaceutical partners, and vascular and wound-closure devices via subsidiaries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersBuford, United States
HQ citystring
Buford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
brachytherapy seeds, medical radioisotope manufacturing, radiopharmaceutical CMO services, fiducial markers, radiation oncology devices
Industry5 codes
1Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
CodeEUAKAIACPrimaryYes
2Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
CodeEUAKAIAAPrimaryNo
3Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)
CodeEUAKAIADPrimaryNo
4Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
CodeHLAIAGAFPrimaryNo
5Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution)
CodeHLAIAGAHPrimaryNo
NAICS code2 codes
  • Irradiation Apparatus Manufacturing334517
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Pharmaceutical Preparations2834
Product category
Brachytherapy Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Brachytherapy Seeds and Products
TypeHardware Sales
Description

Sale of LDR brachytherapy seeds (TheraSeed Pd-103, AgX100 I-125, Cesium-131) and related delivery systems (strands, cartridges, preloaded needles). Products are sold directly to healthcare providers and hospitals for prostate and other cancer treatments.

theragenics.com
2Radioisotope Contract Manufacturing (CMO)
TypeManaged Services
Description

Contract manufacturing services for pharmaceutical companies requiring medical radioisotope production. Theragenics provides large-scale production of isotopes like Copper-64 for radiopharmaceutical partners under manufacturing supply agreements.

theragenics.com
3Fiducial Markers and Accessories
TypeHardware Sales
Description

Sale of gold fiducial markers and related products for radiation therapy guidance. Includes Gold Fiducial Marker Needles and AnchorMarker needles with bio-absorbable polymer design.

theragenics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales
Pricing details1 tier
1B2B contract manufacturing services
ModelOtherBilling cadenceMulti-year contract
Notes

Radioisotope CMO services priced through individual manufacturing supply agreements. No public pricing available.

theragenics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Galt Medical
Description

Leading provider of vascular and interventional medical devices with over 30 years of history, providing quality, reliable access products for interventional procedures

theragenics.com
+2 more records
Core offering1 text field

Theragenics manufactures and sells Low-Dose-Rate (LDR) brachytherapy seeds (Palladium-103 TheraSeed, Iodine-125 AgX100, and Cesium-131), along with complementary delivery systems (strands, cartridges, preloaded needles) and fiducial markers for cancer treatment. The company also operates as a contract manufacturing organization (CMO) producing medical radioisotopes (Copper-64, Palladium-103, Iodine-125, Indium-111, Gallium-67, Yttrium-90) using 14 cyclotrons at a 134,000 sq ft facility in Buford, GA, supplying pharmaceutical and radiopharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 310,000+ brachytherapy seeds supplied by Theragenics alone
+3 more records
Product overview1 text field

Theragenics offers a unified portfolio of brachytherapy products and radioisotope contract manufacturing services. The brachytherapy segment includes TheraSeed® Palladium-103, AgX100® Iodine-125, and Cesium-131 seeds as core brachytherapy implants, along with complementary delivery systems including C20™ seed cartridges, TheraStrand®/TheraSleeve® stranded seed configurations, TheraLoad®/AnchorLoad® non-stranded options, and Preloaded Needle Trays. Fiducial marker offerings include Gold Fiducial Marker Needles and AnchorMarker™ Needles. The radioisotope CMO services produce Copper-64, Palladium-103, Indium-111, Gallium-67, Iodine-125, and Yttrium-90 using 14 cyclotrons at a 134,000 sq ft facility. Subsidiaries include Galt Medical (vascular access devices) and Arrotek (medical device design consultancy).

Product and service14 records
1TheraSeed Palladium-103
CategoryBrachytherapy Seed
Description

Industry-leading Pd-103 LDR brachytherapy seed with 16.9 day half-life and 20-23 keV principal energy; concave end cups for tissue fixity, laser-welded titanium capsule with two Pd-103 plated graphite pellets and lead x-ray marker. Used by radiation oncologists and urologists for prostate and other localized cancer treatment.

2AgX100 Iodine-125
CategoryBrachytherapy Seed
Description

I-125 LDR brachytherapy seed with 59.43-day half-life and 27-35 keV principal energy; stable silver core for optimal imaging clarity and laser-welded titanium capsule. Sold to hospitals and oncology centers for prostate and other cancer brachytherapy procedures.

3Cesium-131 LDR Brachytherapy Seeds
CategoryBrachytherapy Seed
Description

High energy (30.4 KeV) Cs-131 LDR brachytherapy seeds with 9.7 day half-life for faster resolution of patient side effects; uniform dose distribution with less overdosing. Available in loose seeds, strands, cartridges, and braided suture options. Distributed by Theragenics under an authorized distribution arrangement with GT Medical Technologies.

4AnchorSeed Brachytherapy Encapsulated Seeds
CategoryBrachytherapy Seed
Description

Proprietary synthetic bio-absorbable polymer seed encapsulation design that improves seed fixity in tissue, reduces misalignment, and minimizes displacement. Compatible with Mick applicators. Sold to hospitals and oncology centers for brachytherapy procedures.

5C20 Brachytherapy Seed Cartridges
6TheraStrand / TheraStrand RT / TheraSleeve Brachytherapy Stranded Seeds
7TheraLoad / AnchorLoad Preloaded Brachytherapy Needle Trays
8Eye Plaque Brachytherapy Seed Carriers
9Gold Fiducial Marker Needles
10AnchorMarker Needles
11Radioisotope CMO Services (Copper-64, Palladium-103, Iodine-125, Indium-111, Gallium-67, Yttrium-90)
CategoryContract Manufacturing Services
Description

Contract manufacturing services producing medical radioisotopes (Copper-64, Palladium-103, Iodine-125, Indium-111, Gallium-67, Yttrium-90) using 14 cyclotrons at the 134,000 sq ft Buford, GA facility. Services are provided under manufacturing supply agreements to pharmaceutical and radiopharmaceutical partners for clinical trials and commercial-scale production.

12Galt Medical Vascular Access Products
13Arrotek Medical Device Design Services
14CP Medical Wound Closure and Specialty Suture Products
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-25
Description

Large-scale manufacturing supply agreement for copper-64 isotope production at Theragenics' 134,000 sq ft facility with 14 cyclotrons near Atlanta, Georgia. The agreement supports Clarity's anticipated commercial launch of 64Cu-SAR-bisPSMA for prostate cancer imaging, pending Phase III trial completion (AMPLIFY and CLARIFY) and FDA approval. Theragenics' facility can produce approximately 100Ci of copper-64 per day per cyclotron, translating to around 2,000 patient doses per day. This partnership expands Clarity's copper-64 supply network alongside SpectronRx and Nusano.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Theragenics is an authorized distributor of Cesium-131 LDR brachytherapy seeds, which are manufactured by GT Medical Technologies, Inc. (Tempe, AZ). Theragenics distributes Cesium-131 seeds and associated product offerings including loose seeds, strands, cartridges, and braided suture options.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large radiation therapy and radiosurgery equipment vendor offering HDR brachytherapy afterloaders, treatment planning, and related disposables. Competes with Theragenics in the broader radiation oncology/brachytherapy category, though Theragenics specializes in LDR seeds while Elekta's portfolio is broader.

TypeBroad incumbent
Description

Leading global supplier of cyclotrons and integrated radiopharma production solutions, including for medical radioisotope production. Comparable to Theragenics' core cyclotron-based isotope manufacturing infrastructure, though iba sells equipment and turnkey facilities while Theragenics operates its own.

TypeDirect peer
Description

Global radiopharmaceutical manufacturer and CMO producing medical isotopes (Tc-99m, Mo-99, I-131, Lu-177) and offering contract manufacturing services — a direct peer to Theragenics' radioisotope CMO segment and a competitor for radiopharma supply contracts.

TypeBroad incumbent
Description

Through its Varian acquisition, Siemens Healthineers is a major radiation oncology incumbent offering external beam, brachytherapy software, and treatment delivery systems — competing for hospital wallet share that might otherwise fund LDR brachytherapy seeds from Theragenics.

TypeDirect peer
Description

U.S. brachytherapy seed manufacturer (Cs-131 and Pd-103) directly competing with Theragenics' TheraSeed and Cs-131 distribution in prostate and other cancer brachytherapy. Closely comparable specialty medical device peer.

TypeDirect peer
Description

Manufacturer of Cesium-131 brachytherapy seeds (GammaTile therapy for brain tumors and other indications). Theragenics is an authorized distributor of GT's Cs-131 products but also operates in the same brachytherapy space.

TypeDirect peer
Description

Commercial-scale producer of Mo-99/Tc-99m and other medical radioisotopes in the U.S. Comparable to Theragenics' cyclotron-based isotope production business and competes for radiopharma manufacturer supply agreements.

TypeDirect peer
Description

U.S.-based medical isotope production company building large-scale production capacity for radioisotopes used in diagnostics and therapeutics, including Cu-64. Directly competes with Theragenics for radiopharmaceutical CMO contracts (e.g., Clarity Pharmaceuticals' Cu-64 supply network).

TypeEmerging player
Description

Medical device manufacturer with vascular access, interventional, and specialty surgical product lines that overlap with Theragenics' Galt Medical subsidiary. Comparable as a peer across the interventional access business, though Theragenics is more concentrated in brachytherapy and radioisotopes.

TypeDirect peer
Description

Radiopharmaceutical CDMO offering large-scale isotope production and radiolabeling services, including Cu-64 supply to Clarity Pharmaceuticals. Direct competitor to Theragenics in radioisotope CMO and radiopharma contract manufacturing.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Theragenic

Brachytherapy Medical Devicestheragenics.com

Theragenics is a private specialty medical device and radioisotope manufacturer operating 14 cyclotrons at a 134,000 sq ft facility in Buford, GA, producing LDR brachytherapy seeds (Pd-103, I-125, Cs-131), radioisotope CMO services for radiopharmaceutical partners, and vascular and wound-closure devices via subsidiaries.

What Theragenic does

Theragenics Corporation is a private specialty medical device and radioisotope manufacturing company headquartered in Buford, Georgia, founded in 1981 as Nuclear Medicine, Inc. by Georgia Institute of Technology physicists. The company operates two principal business segments: (1) a brachytherapy franchise built around proprietary LDR brachytherapy seeds — TheraSeed® Palladium-103, AgX100® Iodine-125, and (since 2025) Cesium-131 distributed under license from GT Medical Technologies — together with a full ecosystem of delivery systems (TheraStrand®, TheraSleeve®, TheraLoad®, AnchorLoad®, C20™ cartridges, preloaded needle trays, intra-ocular carriers) and fiducial markers; and (2) a radioisotope contract manufacturing organization (CMO) business leveraging 14 cyclotrons at a 134,000 sq ft facility to produce Copper-64, Pd-103, I-125, Indium-111, Gallium-67, and Yttrium-90 for radiopharmaceutical partners, including a March 2026 large-scale Copper-64 supply agreement with Clarity Pharmaceuticals.

The company's business model combines direct sales of brachytherapy seeds and accessories to hospitals, cancer centers, and urology/radiation oncology practices across more than 40 countries, with multi-year B2B contract manufacturing agreements with pharmaceutical partners developing radiopharmaceuticals. GTM is sales-led for the medical device side, supported by industry conference participation (ABS, ASTRO, EANM, LUGPA) and a physician finder tool, while the CMO side is a dedicated B2B channel with named account management. Theragenics operates through wholly-owned subsidiaries Galt Medical (vascular/interventional devices, Garland TX), CP Medical (wound closure and specialty sutures, Norcross GA), and Arrotek Medical (medical device design consultancy with facilities in Sligo, Ireland and North Attleboro, MA). The company is owned by Juniper Investment Company following a mid-2010s take-private transaction.

Theragenic firmographics

Firmographics
Name
Theragenic
Legal name
Theragenics Corporation
Website
https://theragenics.com
Company type
Private
Founded year
1981
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Theragenics is a private specialty medical device and radioisotope manufacturer operating 14 cyclotrons at a 134,000 sq ft facility in Buford, GA, producing LDR brachytherapy seeds (Pd-103, I-125, Cs-131), radioisotope CMO services for radiopharmaceutical partners, and vascular and wound-closure devices via subsidiaries.
Ownership category
akta.pro rank

Theragenic industry classification

Industry
Product category
Brachytherapy Medical Devices
NAICS
Irradiation Apparatus Manufacturing (334517), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
akta.pro primary industry
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)
akta.pro secondary industries
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH)

Keywords

  • Brachytherapy seeds
  • Medical radioisotope manufacturing
  • Radiopharmaceutical CMO services
  • Fiducial markers
  • Radiation oncology devices

Where Theragenic is headquartered

Location

Headquarters

HQ city
Buford
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Theragenic business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales

Revenue model

  1. Brachytherapy Seeds and Products: Sale of LDR brachytherapy seeds (TheraSeed Pd-103, AgX100 I-125, Cesium-131) and related delivery systems (strands, cartridges, preloaded needles). Products are sold directly to healthcare providers and hospitals for prostate and other cancer treatments.
  2. Radioisotope Contract Manufacturing (CMO): Contract manufacturing services for pharmaceutical companies requiring medical radioisotope production. Theragenics provides large-scale production of isotopes like Copper-64 for radiopharmaceutical partners under manufacturing supply agreements.
  3. Fiducial Markers and Accessories: Sale of gold fiducial markers and related products for radiation therapy guidance. Includes Gold Fiducial Marker Needles and AnchorMarker needles with bio-absorbable polymer design.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B contract manufacturing services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Theragenic product offering

Product offering

Core offering

Theragenics manufactures and sells Low-Dose-Rate (LDR) brachytherapy seeds (Palladium-103 TheraSeed, Iodine-125 AgX100, and Cesium-131), along with complementary delivery systems (strands, cartridges, preloaded needles) and fiducial markers for cancer treatment. The company also operates as a contract manufacturing organization (CMO) producing medical radioisotopes (Copper-64, Palladium-103, Iodine-125, Indium-111, Gallium-67, Yttrium-90) using 14 cyclotrons at a 134,000 sq ft facility in Buford, GA, supplying pharmaceutical and radiopharmaceutical partners.

Product overview

Theragenics offers a unified portfolio of brachytherapy products and radioisotope contract manufacturing services. The brachytherapy segment includes TheraSeed® Palladium-103, AgX100® Iodine-125, and Cesium-131 seeds as core brachytherapy implants, along with complementary delivery systems including C20™ seed cartridges, TheraStrand®/TheraSleeve® stranded seed configurations, TheraLoad®/AnchorLoad® non-stranded options, and Preloaded Needle Trays. Fiducial marker offerings include Gold Fiducial Marker Needles and AnchorMarker™ Needles. The radioisotope CMO services produce Copper-64, Palladium-103, Indium-111, Gallium-67, Iodine-125, and Yttrium-90 using 14 cyclotrons at a 134,000 sq ft facility. Subsidiaries include Galt Medical (vascular access devices) and Arrotek (medical device design consultancy).

Differentiator

Problem solved

Functional benefit

Brands

  • Galt Medical: Leading provider of vascular and interventional medical devices with over 30 years of history, providing quality, reliable access products for interventional procedures
  • Galt Medical OEM
  • Arrotek Medical

Products and services

  • TheraSeed Palladium-103 Industry-leading Pd-103 LDR brachytherapy seed with 16.9 day half-life and 20-23 keV principal energy; concave end cups for tissue fixity, laser-welded titanium capsule with two Pd-103 plated graphite pellets and lead x-ray marker. Used by radiation oncologists and urologists for prostate and other localized cancer treatment.
  • AgX100 Iodine-125 I-125 LDR brachytherapy seed with 59.43-day half-life and 27-35 keV principal energy; stable silver core for optimal imaging clarity and laser-welded titanium capsule. Sold to hospitals and oncology centers for prostate and other cancer brachytherapy procedures.
  • Cesium-131 LDR Brachytherapy Seeds High energy (30.4 KeV) Cs-131 LDR brachytherapy seeds with 9.7 day half-life for faster resolution of patient side effects; uniform dose distribution with less overdosing. Available in loose seeds, strands, cartridges, and braided suture options. Distributed by Theragenics under an authorized distribution arrangement with GT Medical Technologies.
  • AnchorSeed Brachytherapy Encapsulated Seeds Proprietary synthetic bio-absorbable polymer seed encapsulation design that improves seed fixity in tissue, reduces misalignment, and minimizes displacement. Compatible with Mick applicators. Sold to hospitals and oncology centers for brachytherapy procedures.
  • C20 Brachytherapy Seed Cartridges
  • TheraStrand / TheraStrand RT / TheraSleeve Brachytherapy Stranded Seeds
  • TheraLoad / AnchorLoad Preloaded Brachytherapy Needle Trays
  • Eye Plaque Brachytherapy Seed Carriers
  • Gold Fiducial Marker Needles
  • AnchorMarker Needles
  • Radioisotope CMO Services (Copper-64, Palladium-103, Iodine-125, Indium-111, Gallium-67, Yttrium-90) Contract manufacturing services producing medical radioisotopes (Copper-64, Palladium-103, Iodine-125, Indium-111, Gallium-67, Yttrium-90) using 14 cyclotrons at the 134,000 sq ft Buford, GA facility. Services are provided under manufacturing supply agreements to pharmaceutical and radiopharmaceutical partners for clinical trials and commercial-scale production.
  • Galt Medical Vascular Access Products
  • Arrotek Medical Device Design Services
  • CP Medical Wound Closure and Specialty Suture Products

Quantifiable outcome

  • 310,000+ brachytherapy seeds supplied by Theragenics alone
  • +3 more outcomes

Companies that use Theragenic

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Theragenic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Theragenic partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Clarity PharmaceuticalscoreStrategic or Co-development Partner · 25 March 2026Large-scale manufacturing supply agreement for copper-64 isotope production at Theragenics' 134,000 sq ft facility with 14 cyclotrons near Atlanta, Georgia. The agreement supports Clarity's anticipated commercial launch of 64Cu-SAR-bisPSMA for prostate cancer imaging, pending Phase III trial completion (AMPLIFY and CLARIFY) and FDA approval. Theragenics' facility can produce approximately 100Ci of copper-64 per day per cyclotron, translating to around 2,000 patient doses per day. This partnership expands Clarity's copper-64 supply network alongside SpectronRx and Nusano.
  • GT Medical TechnologiescoreChannel Partner/ Reseller/ DistributorTheragenics is an authorized distributor of Cesium-131 LDR brachytherapy seeds, which are manufactured by GT Medical Technologies, Inc. (Tempe, AZ). Theragenics distributes Cesium-131 seeds and associated product offerings including loose seeds, strands, cartridges, and braided suture options.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Theragenic competitors and assessment

Company assessment

Broad incumbents

  • Elekta: Large radiation therapy and radiosurgery equipment vendor offering HDR brachytherapy afterloaders, treatment planning, and related disposables. Competes with Theragenics in the broader radiation oncology/brachytherapy category, though Theragenics specializes in LDR seeds while Elekta's portfolio is broader.
  • iba (Ion Beam Applications): Leading global supplier of cyclotrons and integrated radiopharma production solutions, including for medical radioisotope production. Comparable to Theragenics' core cyclotron-based isotope manufacturing infrastructure, though iba sells equipment and turnkey facilities while Theragenics operates its own.
  • Siemens Healthineers (Varian): Through its Varian acquisition, Siemens Healthineers is a major radiation oncology incumbent offering external beam, brachytherapy software, and treatment delivery systems — competing for hospital wallet share that might otherwise fund LDR brachytherapy seeds from Theragenics.

Direct peers

  • Curium Pharma: Global radiopharmaceutical manufacturer and CMO producing medical isotopes (Tc-99m, Mo-99, I-131, Lu-177) and offering contract manufacturing services — a direct peer to Theragenics' radioisotope CMO segment and a competitor for radiopharma supply contracts.
  • IsoRay Medical: U.S. brachytherapy seed manufacturer (Cs-131 and Pd-103) directly competing with Theragenics' TheraSeed and Cs-131 distribution in prostate and other cancer brachytherapy. Closely comparable specialty medical device peer.
  • GT Medical Technologies: Manufacturer of Cesium-131 brachytherapy seeds (GammaTile therapy for brain tumors and other indications). Theragenics is an authorized distributor of GT's Cs-131 products but also operates in the same brachytherapy space.
  • NorthStar Medical Radioisotopes: Commercial-scale producer of Mo-99/Tc-99m and other medical radioisotopes in the U.S. Comparable to Theragenics' cyclotron-based isotope production business and competes for radiopharma manufacturer supply agreements.
  • Nusano: U.S.-based medical isotope production company building large-scale production capacity for radioisotopes used in diagnostics and therapeutics, including Cu-64. Directly competes with Theragenics for radiopharmaceutical CMO contracts (e.g., Clarity Pharmaceuticals' Cu-64 supply network).
  • SpectronRx: Radiopharmaceutical CDMO offering large-scale isotope production and radiolabeling services, including Cu-64 supply to Clarity Pharmaceuticals. Direct competitor to Theragenics in radioisotope CMO and radiopharma contract manufacturing.

Emerging players

  • Teleflex: Medical device manufacturer with vascular access, interventional, and specialty surgical product lines that overlap with Theragenics' Galt Medical subsidiary. Comparable as a peer across the interventional access business, though Theragenics is more concentrated in brachytherapy and radioisotopes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Theragenic social profiles

Digital presence

Theragenic compliance and trust

Trust signal

Compliance2 records

Theragenic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Theragenic leadership team

Management profile

Number of profiles

Profiles4 records

Theragenic subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Theragenic funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Theragenic M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theragenic

What does Theragenic do?

Theragenics manufactures and sells Low-Dose-Rate (LDR) brachytherapy seeds (Palladium-103 TheraSeed, Iodine-125 AgX100, and Cesium-131), along with complementary delivery systems (strands, cartridges, preloaded needles) and fiducial markers for cancer treatment. The company also operates as a contract manufacturing organization (CMO) producing medical radioisotopes (Copper-64, Palladium-103, Iodine-125, Indium-111, Gallium-67, Yttrium-90) using 14 cyclotrons at a 134,000 sq ft facility in Buford, GA, supplying pharmaceutical and radiopharmaceutical partners.

Is Theragenic a public or private company?

Theragenic is a private company. It is classified as private equity controlled and is currently operating.

When was Theragenic founded?

Theragenic was founded in 1981. It employs 501 to 1,000 people.

Where is Theragenic based?

Theragenic is headquartered in Buford, United States, in the North America region.

How does Theragenic make money?

Three revenue lines are on record. Brachytherapy Seeds and Products are the primary driver. The others are radioisotope Contract Manufacturing (CMO) and fiducial Markers and Accessories.

Who are Theragenic's main competitors?

Broad incumbents on record are Elekta, iba (Ion Beam Applications) and Siemens Healthineers (Varian). Direct peers are Curium Pharma, IsoRay Medical, GT Medical Technologies, NorthStar Medical Radioisotopes, Nusano and SpectronRx. Teleflex is listed as an emerging player.

Does Theragenic have an API?

No public API is recorded for Theragenic.

What industry is Theragenic in?

Theragenic's product category is Brachytherapy Medical Devices. Its primary akta.pro industry code is EUAKAIAC, Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC), with a secondary code of EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.). Its NAICS code is 334517 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comClarity Pharmaceuticals signs copper-64 supply deal with Theragenics By Investing.comClarity Pharmaceuticals has entered into a manufacturing supply agreement with Theragenics for large-scale copper-64 production at Theragenics' 134,000 square foot facility near Atlanta, Georgia, which operates 14 cyclotrons and can produce approximately 100Ci of copper-64 per day on a single cyclotron. The agreement is intended to support the anticipated commercial launch of Clarity's 64Cu-SAR-bisPSMA product, pending completion of Phase III trials AMPLIFY and CLARIFY and subsequent FDA approval. The company recently achieved its target enrollment number in the AMPLIFY trial, though the stock has declined 14.72% over the past week despite analyst consensus of a strong buy rating.PR NewswireClarity signs a large-scale Manufacturing Supply Agreement for copper-64 with TheragenicsClarity Pharmaceuticals signed a large-scale Manufacturing Supply Agreement with Theragenics for copper-64 production at Theragenics' 134,000 square foot facility with 14 cyclotrons near Atlanta, Georgia. Theragenics has capacity to produce approximately 100Ci of copper-64 per day per cyclotron, translating to around 2,000 patient doses per day, supporting Clarity's anticipated commercial launch of 64Cu-SAR-bisPSMA pending successful Phase III trial completion and FDA approval. The agreement expands Clarity's existing copper-64 supply network alongside SpectronRx and Nusano, designed to support commercial-scale demand across multiple oncology indications.Small CapsClarity Pharma Secures Key Supply Deal to Boost Commercialisation of Prostate Cancer AgentClarity Pharmaceuticals has signed a large-scale manufacturing supply agreement with Theragenics for copper-64 isotope production to support its lead prostate cancer agent 64Cu-SAR-bisPSMA, securing capacity for up to 2,000 patient doses per day per cyclotron at Theragenics' 14-cyclotron facility near Atlanta, Georgia. The company is advancing toward potential FDA NDA approval following positive Phase III trial data, with the AMPLIFY trial exceeding its recruitment target and recent clinical results showing the agent outperformed standard-of-care imaging in detecting lesions. Despite reporting a 136% increase in half-year losses to $55.6 million with no revenue from ordinary activities, Clarity views the supply agreement as a critical step toward establishing a robust commercial supply network for its radiopharmaceutical pipeline.YahooGT Medical and Theragenics team up to expand access to radiotherapy seedsGT Medical Technologies and Theragenics Corporation have entered an agreement where Theragenics becomes the exclusive distributor of Cesium-131 brachytherapy seeds for non-brain cancer treatments. GT Medical, which acquired these assets from Isoray Medical in December 2023, will continue to manufacture the isotopes while focusing its product strategy on its FDA-approved GammaTile therapy for brain tumours.PR NewswireGT Medical Technologies, Inc. and Theragenics Corporation Forge Distribution Partnership for Cesium-131GT Medical Technologies, Inc. has entered into a strategic distribution partnership with Theragenics Corporation, making Theragenics the exclusive distributor of Cesium-131 brachytherapy seeds and carriers for non-brain cancer treatments, including prostate cancer. GT MedTech, as the sole manufacturer of Cesium-131, will continue focusing on expanding its FDA-cleared GammaTile therapy for operable brain tumors in the United States. The partnership aims to broaden physician access to brachytherapy options and advance cancer care delivery.PR NewswireC4 Imaging Announces First Prostate Cancer Treatment Utilizing Orion™ HDR MRI MarkersC4 Imaging LLC announced the first prostate cancer treatment using its Orion™ HDR MRI Markers, performed by Dr. Peter Rossi at the Calaway Young Cancer Center in Glenwood Springs, Colorado. The Orion™ device enables MRI-based treatment planning for high dose rate brachytherapy, offering better anatomical detail than traditional CT-guided methods and potentially reducing side effects. C4 Imaging's commercial partner Theragenics played a role in introducing the technology to Dr. Rossi's team.GlobeNewswireEckert & Ziegler to sell US seed businessEckert & Ziegler BEBIG's board approved selling its US seed business to Theragenics Corporation, expected to close by end of 2015. The sale follows failed attempts to regain profitability after FDA quality issues. The company will focus on higher-margin afterloader business.GlobeNewswireAdvanced Radiation Therapy Selects Theragenics Corporation to Distribute Its AccuBoost TechnologyAdvanced Radiation Therapy announced an agreement with Theragenics Corporation to make Theragenics its US distributor for AccuBoost targeted partial breast irradiation technology. The non-invasive treatment offers an alternative to Accelerated Partial Breast Irradiation for women choosing Breast Conserving Therapy. Theragenics will commence sales and marketing to expand AccuBoost's US presence.